TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7483799
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of oral poliomyelitis (OPV) and diphtheria and tetanus (DTV) vaccines
Study: 7483799
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of OPV and DTV vaccines plus recombinant hepatitis B vaccine (HBV)
Study: 7483799
Drug: HBV recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV recombinant vaccine alone
Study: 16775229
Drug: Ibuprofen 200
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 200 to 400 mg
Study: 7821102
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg erythromycin
Study: 11293641
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg co-amoxiclav (250 mg amoxicillin and 125 mg clavulanic acid)
Study: 11293641
Drug: both antibiotics
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: both antibiotics (erythromycin and co-amoxiclav)
Study: 18603947
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with combination of permanent and releasable scleral flap sutures (Group B)
Study: 12585979
Drug: HSV-2 vaccine
Normalized name: HSV-2 theracine
DrugBank: HSV-2 theracine (DB05811)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSV-2 vaccine
Study: 1394809
Drug: Intravesical instillations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillations of Adriamycin (ADM) at 20 mg/40 ml physiological saline for 2 years after TUR (Group A)
Study: 1394809
Drug: Intravesical instillations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillations of Adriamycin (ADM) at 20 mg/40 ml physiological saline for 2 weeks before TUR (Group B)
Study: 28965100
Drug: Oral resveratrol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral resveratrol, 40 mg (two caplets) two times per day for 1 week, then 20 mg (one caplet) two times per day for a total of 6 months
Study: 28965100
Drug: Oral resveratrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral resveratrol
Study: 23948785
Drug: Acetyl-L-carnitine (1000-3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (1000-3000 mg daily) plus α-lipoic acid (600-1800 mg daily)
Study: 21615419
Drug: Testosterone (1000mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (1000mg intramuscular long-acting testosterone undecanoate)
Study: 21615419
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (33μg)
Study: 18329882
Drug: Porous coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porous coated prosthesis with solution-deposited HA
Study: 15552357
Drug: Cues receiving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cues receiving strong inputs from other associates (e.g., car)
Study: 11172852
Drug: Tibolone plus
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone plus GnRH analogue (leuprolide acetate and iron tablets)
Study: 11172852
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus GnRH analogue (leuprolide acetate and iron tablets)
Study: 11172852
Drug: GnRH analogue
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH analogue (leuprolide acetate and iron tablets)
Study: 7837950
Drug: Hypocaloric diet
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric diet (HD) therapy
Study: 3287534
Drug: Aminophylline (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (1-2 mg/kg)
Study: 29668352
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (fluticasone furoate 100 μg, umeclidinium 62.5 μg, vilanterol 25 μg)
Study: 29668352
Drug: Fluticasone furoate-vilanterol
Normalized name: Fluticasone Furoate-Vilanterol Ellipta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate-vilanterol (100 μg and 25 μg)
Study: 29668352
Drug: Umeclidinium-vilanterol (62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium-vilanterol (62.5 μg and 25 μg)
Study: 21105284
Drug: Bepotastine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepotastine (10 mg)
Study: 18410464
Drug: Diphenhydramine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (30 mg)
Study: 16822134
Drug: Gaze direction
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaze direction and concurrent auditory temporal information
Study: 12798894
Drug: P1 medium
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: P1 medium supplemented with 0.5 mg/mL hyaluronic acid for 5‐10 min before intrauterine transfer
Study: 11004052
Drug: Hyaluronidase 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronidase 3.75 IU/mL
Study: 11004052
Drug: Hyaluronidase 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronidase 7.5 IU/mL
Study: 8770965
Drug: Enalaprilat (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat (10 mg i.v.)
Study: 8770965
Drug: Exogenous angiotensin
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous angiotensin II infusion
Study: 1628410
Drug: Nicardipine slow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine slow release 40 mg twice daily
Study: 31606364
Drug: Mineralocorticoid antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Mineralocorticoid antagonists (MRAs) therapy maintained or increased during hospitalization
Study: 31606364
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) maintained or increased during hospitalization
Study: 31606364
Drug: Down-titration of
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Down-titration of MRAs during hospitalization
Study: 30307304
Drug: L-arginine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (7 g)
Study: 30307304
Drug: L-arginine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (7 g) alone (L-ARG)
Study: 30307304
Drug: EX-LARG (L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: EX-LARG (L-arginine + exercise)
Study: 25228130
Drug: Continuous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous insulin infusion during surgery (n = 33)
Study: 22410137
Drug: 4-month daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-month daily rifampicin regimen (4R); n = 190
Study: 22410137
Drug: 6-month daily
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month daily isoniazid regimen (6H); n = 183
Study: 19111163
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy (SCIT) with alum-formulated recombinant human GAD65
Study: 15879822
Drug: Active electromagnetic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active electromagnetic therapy (15 minutes at 10 Hz followed by 15 minutes at 50 Hz, twice weekly for 4 weeks)
Study: 12743130
Drug: Cisplatin-based intraperitoneal
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based intraperitoneal treatment
Study: 8867677
Drug: Monthly replacement
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly replacement schedule
Study: 8867677
Drug: Three monthly
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three monthly replacement schedule
Study: 3986081
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg doses of caffeine as an aqueous oral solution
Study: 3986081
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg doses of caffeine as an intravenous infusion
Study: 25917561
Drug: Prasugrel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (60 mg)
Study: 25917561
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg)
Study: 20862933
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with speech therapy
Study: 20862933
Drug: Speech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech therapy only (Control)
Study: 22795211
Drug: d-serine 2
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-serine 2 g/d
Study: 12704001
Drug: CAF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF regimen (Cytoxan 600 mg/m(2), Adriamycin 60 mg/m(2), 5‐FU 600 mg/m(2))
Study: 12704001
Drug: TP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP regimen (paclitaxel 135 mg/m(2), cisplatin 60 mg/m(2))
Study: 8607102
Drug: Intermittent regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent regional therapy with 20 mg rt-PA for 4 h each day
Study: 8607102
Drug: Systemic thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic thrombolytic therapy with 20 mg rt-PA for 4 h each day
Study: 8607102
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (intermittent regional and systemic thrombolytic therapy)
Study: 1103743
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied griseofulvin in alcohol solution
Study: 27577562
Drug: Mentalization-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-based treatment (MBT)
Study: 21226754
Drug: Nurse-administered minimal
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-administered minimal psychological intervention
Study: 16635651
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (drug-free subjects)
Study: 1358004
Drug: Atracurium 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.50 mg.kg‐1
Study: 1358004
Drug: Vecuronium 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.10 mg.kg‐1
Study: 25258045
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy and exercise interventions
Study: 23517382
Drug: Autologous noncultured
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous noncultured epidermal cell suspension (NCES)
Study: 18346604
Drug: Bupivacaine 0.125%
Normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.125% + morphine
Study: 18346604
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% + morphine
Study: 15892618
Drug: Bevacizumab (Avastin)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (Avastin) in combination with gemcitabine for pancreatic cancer
Study: 12009370
Drug: One transcervical
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One transcervical insertion of 252 mg of quinacrine
Study: 12009370
Drug: Two transcervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two transcervical insertions of 252 mg of quinacrine
Study: 7775186
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg meperidine with 25 mg promethazine IM
Study: 7775186
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg dihydroergotamine with 10 mg metoclopramide IV
Study: 2190629
Drug: Cadralazine 10
Normalized name: cadralazine
DrugBank: Cadralazine (DB13452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadralazine 10 mg oral dose
Study: 30025177
Drug: 4.5 g
Normalized name: Zosyn 4.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 g of intravenous MgSO4 (low-dose group)
Study: 30025177
Drug: 9 g
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g of intravenous MgSO4 (high-dose group)
Study: 30025177
Drug: Serum saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum saline infusion (placebo group)
Study: 24848793
Drug: Synbiotic capsules
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic capsules containing 200 million of seven strains of friendly bacteria plus fructo‐oligosaccharide, twice a day for 28 weeks
Study: 24848793
Drug: Placebo capsules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, twice a day for 28 weeks
Study: 19084376
Drug: Enriched milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enriched milk (500 mL/d)
Study: 19084376
Drug: Skimmed milk
Normalized name: Calcium fortified skimmed milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skimmed milk (500 mL/d)
Study: 19084376
Drug: Semi-skimmed milk
Normalized name: Calcium fortified semi-skimmed milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-skimmed milk (500 mL/d)
Study: 11990912
Drug: Single 400-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 400-mg fluconazole dose
Study: 9226511
Drug: Dexamethasone 0.5
Normalized name: dexamethasone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.5 mg administered nightly with gonadotropin therapy
Study: 9226511
Drug: Gonadotropin therapy
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin therapy without dexamethasone (control group)
Study: 2890509
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg (three times)
Study: 28043163
Drug: Medication Adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Adherence Report Scale (MARS)
Study: 30027281
Drug: IPC +
Normalized name: CAP,IPC VALVE ROCKET #54410
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPC + low-molecular-weight (LMW) heparin sodium
Study: 30027281
Drug: IPC +
Normalized name: CAP,IPC VALVE ROCKET #54410
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPC + LMW heparin sodium
Study: 15956124
Drug: Tecadenoson (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecadenoson (various doses)
Study: 10878628
Drug: iodixanol (Visipaque)
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iodixanol (Visipaque) 320 mg I/ml
Study: 10878628
Drug: iohexol (Omnipaque)
Normalized name: Iohexol
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iohexol (Omnipaque) 350 mg I/ml
Study: 9426846
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin D3 (Calcijex and injectable One‐Alpha)
Study: 9426846
Drug: Oral One‐Alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral One‐Alpha
Study: 3886399
Drug: BAY l
Normalized name: Bay Leaf
DrugBank: Laurus nobilis (DB10670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY l 5240 (nifedipine 10 mg + acebutolol 100 mg)
Study: 2465650
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy with methotrexate (MTX) and 5-fluorouracil (5FU)
Study: 2465650
Drug: Intra-venous CMFV
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-venous CMFV treatment (in cases with objective remission)
Study: 2465650
Drug: Systemic FACV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic FACV combination
Study: 28340118
Drug: Group Music
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Music Therapy (GMT)
Study: 26270586
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg IV dexamethasone
Study: 24086815
Drug: Silver zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver zinc sulfadiazine cream (AgZnSD)
Study: 19892663
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) at 500 mg/m(2)
Study: 19892663
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) at 750 mg/m(2)
Study: 19892663
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) at 1,000 mg/m(2)
Study: 15538094
Drug: losartan/hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan/hydrochlorothiazide (50 mg/12.5 mg)
Study: 2430180
Drug: Oral tetrahydroaminoacridine
Normalized name: Tetrahydroaminoacridine
DrugBank: Tacrine (DB00382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tetrahydroaminoacridine (THA)
Study: 30500141
Drug: Dapsone gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone gel, 7.5%
Study: 25008127
Drug: Web-based guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based guided self-help intervention (Happy@Work), consisting of 6 lessons of problem-solving treatment and cognitive therapy, with weekly assignments and feedback from a coach.
Study: 20688462
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg of rhTSH IV 24 h before (123)I
Study: 20688462
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg of rhTSH IV 48 h before (123)I
Study: 18279973
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) session
Study: 10322096
Drug: Alpha1-proteinase inhibitor
Normalized name: Alpha1-proteinase inhibitor
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha1-proteinase inhibitor therapy (four intravenous doses)
Study: 7497557
Drug: Mivacurium 2
Normalized name: mivacurium 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 2 x ED95 (0.150 mg.kg‐1) with priming
Study: 7497557
Drug: Mivacurium 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 3 x ED95 (0.215 mg.kg‐1) with priming
Study: 8042808
Drug: Succinylcholine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (1 mg.kg‐1)
Study: 7497557
Drug: Mivacurium 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 1 x ED95 (0.075 mg.kg‐1) with priming
Study: 2742729
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg d-amphetamine
Study: 12066946
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg mifepristone as a single dose
Study: 12066946
Drug: Yuzpe regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yuzpe regimen (two tablets each with 50 microg ethinyloestradiol and 0.25 mg levonorgestrel, repeated 12 hours later)
Study: 7649072
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily for 6 weeks
Study: 2678424
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg three times daily)
Study: 26974214
Drug: Risperidone long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone long-acting injectable 50 mg
Study: 26974214
Drug: Risperidone long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone long-acting injectable 25 mg
Study: 22370535
Drug: Pranlukast dry
Normalized name: pranlukast
DrugBank: Pranlukast (DB01411)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Pranlukast dry syrup (PLK DS)
Study: 18681749
Drug: Risperidone (0.25-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.25-2 mg/day)
Study: 9043896
Drug: 150 IU
Normalized name: Follitropin Beta 150 IU/0.5 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU FSH administered to husbands, either i.m. or s.c., three times a week, starting 3 months before IUI cycles and maintained until the fifth IUI cycle
Study: 9043896
Drug: 150 IU
Normalized name: Follitropin Beta 150 IU/0.5 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU FSH administered to husbands
Study: 3358881
Drug: Pindolol 5
Normalized name: pindolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 5 mg three times daily
Study: 6111212
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg daily
Study: 29088928
Drug: Lithium (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (target serum concentration, 0.80-0.99 mEq/L)
Study: 29088928
Drug: Divalproex (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divalproex (target serum valproate concentration, 80-99 μg/mL)
Study: 18007568
Drug: Adjunctive risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adjunctive risperidone
Study: 25103148
Drug: Imiquimod, 5%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod, 5%, cream (44 patients)
Study: 25103148
Drug: Intralesional Mycobacterium
Normalized name: Mycobacterium phlei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional Mycobacterium w (Mw) vaccine (45 patients)
Study: 19170911
Drug: Magnetocardiography (MCG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetocardiography (MCG) after electrical cardioversion (CV)
Study: 19170911
Drug: Magnetocardiography (MCG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetocardiography (MCG) after 1 month in SR
Study: 17586422
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (PUFAs) 1.7 g
Study: 18436564
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (olive oil)
Study: 14513268
Drug: Alfacalcidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (1 microg) plus calcium (500 mg)